Cabozantinib In Advanced Neuroendocrine Tumors
1. Progression-free survival had a hazard ratio of 0.38 (extrapancreatic NETs) and 0.23 (pancreatic NETs) for those treated with cabozantinib ...
Tag: NET
177Lu-Dotatate plus octreotide was not superior in overall survival compared to octreotide alone for neuroendocrine tumours
1. The median overall survival for patients receiving177Lu-Dotatate and intramuscular, long-acting octreotide was 47.0 months and 36.3 months respectively 2. ...